AU2003221497A1 - Pharmaceutical microparticles - Google Patents

Pharmaceutical microparticles

Info

Publication number
AU2003221497A1
AU2003221497A1 AU2003221497A AU2003221497A AU2003221497A1 AU 2003221497 A1 AU2003221497 A1 AU 2003221497A1 AU 2003221497 A AU2003221497 A AU 2003221497A AU 2003221497 A AU2003221497 A AU 2003221497A AU 2003221497 A1 AU2003221497 A1 AU 2003221497A1
Authority
AU
Australia
Prior art keywords
pharmaceutical microparticles
microparticles
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003221497A
Other languages
English (en)
Inventor
Michael Ausborn
Olivier Lambert
Oskar Nagele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2003221497A1 publication Critical patent/AU2003221497A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2003221497A 2002-03-13 2003-03-12 Pharmaceutical microparticles Abandoned AU2003221497A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10211040 2002-03-13
DE10211040.9 2002-03-13
DE10213856.7 2002-03-27
DE10213856 2002-03-27
PCT/EP2003/002565 WO2003075892A1 (en) 2002-03-13 2003-03-12 Pharmaceutical microparticles

Publications (1)

Publication Number Publication Date
AU2003221497A1 true AU2003221497A1 (en) 2003-09-22

Family

ID=27806083

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003221497A Abandoned AU2003221497A1 (en) 2002-03-13 2003-03-12 Pharmaceutical microparticles

Country Status (5)

Country Link
US (4) US20050152980A1 (cg-RX-API-DMAC7.html)
EP (1) EP1485070A1 (cg-RX-API-DMAC7.html)
JP (3) JP4679822B2 (cg-RX-API-DMAC7.html)
AU (1) AU2003221497A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003075892A1 (cg-RX-API-DMAC7.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075892A1 (en) * 2002-03-13 2003-09-18 Novartis Ag Pharmaceutical microparticles
MY158342A (en) 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
JP2008530206A (ja) * 2005-02-17 2008-08-07 メディバス エルエルシー ポリマー粒子送達組成物および使用法
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
KR100682334B1 (ko) * 2006-07-14 2007-02-16 (주)지에프씨 미립상 레시틴 왁스 조성물 제조장치
CN100540585C (zh) * 2006-08-02 2009-09-16 四川大学 含磷脂酰胆碱基团的可生物降解聚酯及其制备方法
AU2008310956B2 (en) * 2007-10-08 2014-08-07 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
US20110223216A1 (en) * 2008-11-17 2011-09-15 Wayne State University Nanoparticles and Porous Particles and Methods of Making the Same
AU2010259184B2 (en) 2009-06-09 2015-08-13 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
US9211377B2 (en) 2009-07-30 2015-12-15 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
SMT202200355T1 (it) 2011-12-16 2022-11-18 Modernatx Inc Composizioni di mrna modificato
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
US20170204152A1 (en) 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
DE112015005320T5 (de) * 2014-11-25 2017-08-31 Cbc Co., Ltd. Janus Nanopartikel und Verfahren zur Herstellung derselben
ES2910425T3 (es) 2015-09-17 2022-05-12 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
US10953103B2 (en) 2015-11-06 2021-03-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V Composition comprising a biocompatible and biodegradable polymer, nanocarriers and a drug and methods of making and using the same
WO2017099823A1 (en) 2015-12-10 2017-06-15 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
EP4036079B1 (en) 2015-12-22 2025-11-19 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
LT3394093T (lt) 2015-12-23 2022-04-25 Modernatx, Inc. Ox40 ligandus koduojančių polinukleotidų naudojimo būdai
WO2017120612A1 (en) 2016-01-10 2017-07-13 Modernatx, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
MX391377B (es) * 2016-05-13 2025-03-21 Merck Patent Gmbh Tamaño de particula y distribucion de polimero para aplicacion de extrusion de fusion.
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
JP2018095616A (ja) * 2016-12-15 2018-06-21 国立大学法人 宮崎大学 アドレノメデュリン徐放性製剤
WO2018170336A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
AU2018234814B2 (en) 2017-03-15 2022-06-30 Modernatx, Inc. Crystal forms of amino lipids
RS63953B1 (sr) 2017-03-15 2023-02-28 Modernatx Inc Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
WO2018232120A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
AU2019258844B2 (en) 2018-04-27 2025-01-30 Fresh Inset S.A. Compositions and articles comprising complexes of 1-methylcycloproprene and alpha-cyclodextrin
EP3852732A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Peg lipids and uses thereof
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CA3141857A1 (en) * 2019-04-23 2020-10-29 Amgen Inc. The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations
US20230210763A1 (en) * 2019-09-19 2023-07-06 Amw Gmbh Extruded depot form for controlled active substance release
AR120080A1 (es) 2019-09-19 2022-02-02 Modernatx Inc Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos
PE20230411A1 (es) 2020-02-03 2023-03-07 Fresh Inset S A Composiciones estables de 1-metilciclopropeno y usos de las mismas
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5432436B2 (cg-RX-API-DMAC7.html) * 1972-05-13 1979-10-15
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US5948441A (en) * 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
DE3917617A1 (de) * 1989-05-31 1990-12-06 Boehringer Ingelheim Kg Mikronisierte bioabbaubare partikel, verfahren zur ihrer herstellung und ihre verwendung
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
DE3934656A1 (de) 1989-10-13 1991-04-18 Schering Ag Verfahren zur herstellung von waessrigen dispersionen
ATE102022T1 (de) * 1990-08-30 1994-03-15 Senju Pharma Co Zusammensetzung zur kontrollierten abgabe von medikamenten.
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US6090925A (en) * 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
EP1649850A1 (en) * 1993-11-19 2006-04-26 Alkermes Controlled Therapeutics Inc. II Preparation of biodegradable microparticles containing a biologically active agent
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
AU4755696A (en) * 1995-01-05 1996-07-24 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Surface-modified nanoparticles and method of making and using same
US5718922A (en) * 1995-05-31 1998-02-17 Schepens Eye Research Institute, Inc. Intravitreal microsphere drug delivery and method of preparation
DE19545257A1 (de) * 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
AU733867B2 (en) * 1996-06-24 2001-05-31 Euro-Celtique S.A. Methods for providing safe local anesthesia
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
WO2000003660A1 (en) * 1998-07-17 2000-01-27 Skyepharma, Inc. Biodegradable compositions for the controlled release of encapsulated substances
GB9906695D0 (en) * 1999-03-24 1999-05-19 Secr Defence Vaccine composition
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
ATE462413T1 (de) * 2000-01-14 2010-04-15 Univ Brown Res Found Verfahren zur herstellung von mikronisierte gefriergetrocknete partikeln
US20030064105A1 (en) * 2000-08-25 2003-04-03 Myung-Jin Kim Lipophilic-coated microparticle containing a protein drug and formulation comprising same
WO2001055360A1 (en) * 2000-01-28 2001-08-02 Infimed Therapeutics, Inc. Slow release protein polymers
AU2001252588A1 (en) * 2000-04-28 2001-11-12 Tanabe Seiyaku Co., Ltd. Method for preparing microsphere
WO2003075892A1 (en) * 2002-03-13 2003-09-18 Novartis Ag Pharmaceutical microparticles
AU2003288902A1 (en) * 2002-09-06 2004-04-08 Genteric, Inc. Microcapsules and methods of use
US20080286375A1 (en) * 2005-11-15 2008-11-20 Amorepacific Corporation Method for Preparing Sustained-Release Microparticles Comprising Sucrose Acetate Isobutyrate

Also Published As

Publication number Publication date
JP2014058580A (ja) 2014-04-03
WO2003075892A1 (en) 2003-09-18
US20050152980A1 (en) 2005-07-14
US20130236550A1 (en) 2013-09-12
US20080279955A1 (en) 2008-11-13
US8110224B2 (en) 2012-02-07
JP2010248271A (ja) 2010-11-04
US8460709B2 (en) 2013-06-11
EP1485070A1 (en) 2004-12-15
JP2005519944A (ja) 2005-07-07
US20120107408A1 (en) 2012-05-03
JP4679822B2 (ja) 2011-05-11

Similar Documents

Publication Publication Date Title
AU2003221497A1 (en) Pharmaceutical microparticles
AU2003291103A1 (en) Pharmaceutical composition
GB0218625D0 (en) Pharmaceutical compounds
AU2003288083A1 (en) Pharmaceutical pellets comprising tamsulosin
AU2003250372A1 (en) Pharmaceutical composition
GB0215775D0 (en) Pharmaceutical compounds
AU2003287705A1 (en) Self-folding polymer microparticles
AU2002364468A1 (en) Solid orally-dispersible pharmaceutical formulation
AU2003212776A1 (en) Microparticles
HUP0303948A2 (hu) Szájban diszpergálódó szilárd gyógyszerforma
AU2003264406A1 (en) Drug or cosmetic
GB0206505D0 (en) Pharmaceutical combination
GB0201520D0 (en) Pharmaceutical uses
PL373409A1 (en) Pharmaceutical combination
GB0204392D0 (en) Pharmaceutical compound
PL355453A1 (en) Pharmaceutical agent
AUPS188302A0 (en) Pharmaceutical composition
HK1072601A (en) Pharmaceutical combination
AU2003238900A1 (en) Pharmaceutical formulation
HK1081845A (en) Pharmaceutical composition comprising octreotide microparticles
AU2003207055A1 (en) Novel drugs for external use
AU2003303963A1 (en) Drug target
GB0224680D0 (en) Pharmaceutical
AU2002951463A0 (en) Pharmaceutical suppressant
AUPS208402A0 (en) Pharmaceutical derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase